Streamlining Tech Transfer And Advancing Next Generation CAR T Therapies

In this final segment of Cell & Gene Live, Designing Early Manufacturing For Long-Term Success In CGT, Raymond Luke, Senior Director of MSAT at Verismo Therapeutics and Todd Luman, Executive Director of Process and Product Development at Allogene, Luman emphasizes that early engagement between R&D, process development, and manufacturing teams is critical for smooth tech transfer to CDMOs, including using scale-down models, documenting processes thoroughly, and collaborating closely with CDMO staff. Luke adds that autologous cell therapy requires treating CDMOs as true partners due to patient-to-patient variability and the need for flexibility, contrasting with traditional small-molecule approaches.